{"id":"NCT01788358","sponsor":"Bayer","briefTitle":"Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension","officialTitle":"Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects With Moderate to Severe Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-14","primaryCompletion":"2014-05-01","completion":"2014-05-01","firstPosted":"2013-02-11","resultsPosted":"2015-08-17","lastUpdate":"2017-10-24"},"enrollment":508,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","otherNames":[]},{"type":"DRUG","name":"Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","otherNames":[]},{"type":"DRUG","name":"Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","otherNames":[]},{"type":"DRUG","name":"Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","otherNames":[]}],"arms":[{"label":"Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)","type":"EXPERIMENTAL"}],"summary":"This study examines the long term safety and efficacy of the Fixed Dose combination BAY98-7106 (nifedipine plus candesartan primarily at the highest dose in development) in patients with moderate to severe hypertension.\n\nPatients meeting the entry criteria, will receive the Fixed Dose combination for 28 weeks, including 8 weeks with stepwise dose increase up to the high target dose. The first 200 subjects completing 28 weeks will continue treatment for additional 24 weeks (52 weeks in total).\n\nSubjects who do not tolerate an increased dose will be treated at their highest tolerable dose.","primaryOutcome":{"measure":"Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28","timeFrame":"From the time of first study drug administration up to Week 28","effectByArm":[{"arm":"Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)","deltaMin":390,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":12},"locations":{"siteCount":82,"countries":["United States","Belgium","Canada","Germany","Poland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":508},"commonTop":["Oedema peripheral","Oedema","Dizziness","Headache","Nasopharyngitis"]}}